Rare leukaemia survival-rate breakthrough

August 13, 2013

A pioneering genetic study means that children with a rare subtype of leukaemia have 75% less chance of their leukaemia recurring.

A study by Newcastle University scientists, published online in the Journal of Clinical Oncology, has shown that lives have already been saved as a result of identifying carrying a chromosomal abnormality known as iAMP21, and giving these patients a very intensive .

Overall survival for acute (ALL) patients, a cancer of the , is now very high, with up to 90% of children being cured. A minority of patients, however, still do not respond to standard treatment.

A decade ago, the same scientists, funded by the charity Leukaemia & Lymphoma Research, discovered the genetic error known as iAMP21. This abnormality occurs when parts of chromosome 21 – one of 23 pairs of chromosomes that contain our genetic instructions – are copied and shuffled around, resulting in extra copies of some genes. The researchers found that this abnormality was present in around 2% of children diagnosed with ALL and that it gave them much greater chance of suffering a relapse.

The team, led by Professor Christine Harrison and Professor Anthony Moorman from the Leukaemia Research Cytogenetics Group, tracked the progress of patients with iAMP21 using samples from clinical trials between 1997 and 2002. They found that more than 80% of patients with iAMP21 had relapsed, compared to less than for 25% for children overall. The long-term survival for the iAMP21 group was also much lower.

Since 2003, bone marrow samples from every child diagnosed with ALL have been tested for the presence of iAMP21 using a genetic test known as 'fluorescence in situ hybridisation' (FISH), which binds glowing tags to DNA and "lights-up" the abnormal sequences. Children with iAMP21 registered on the UKALL2003 trial, which was funded by Leukaemia & Lymphoma Research and the Medical Research Council, were immediately recommended for treatment using a very intensive protocol.

The results of the UKALL2003 trial show that if children with iAMP21 are treated with intensive chemotherapy they have a dramatically reduced risk of relapse. In addition the proportion surviving for five years or more increased to nearly 90%.

Anthony Moorman, Professor of Genetic Epidemiology at Newcastle University, said: "Although using the presence of genetic abnormalities to guide treatment is not new within childhood leukaemia, such a clear demonstration of its beneficial impact on is extremely rare. In time we may be able to design drugs to actually target the iAMP21 abnormality, sparing these children from toxic treatment."

Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, said: "By establishing how different genetic abnormalities found in leukaemia cells dictate how well the child will respond to treatment, we can identify high-risk patients early on. These new results demonstrate the huge potential of personalised medicine."

Explore further: Scientists identify genetic drivers of leukaemia

Related Stories

Scientists identify genetic drivers of leukaemia

August 2, 2012
(Medical Xpress) -- Scientists at Newcastle University have discovered three key genetic errors which can dictate how adult patients develop leukaemia and respond to treatment and could help doctors adapt future treatments.

Scientists seek out cancer cells hiding from treatment

January 15, 2013
Scientists hope to improve leukaemia treatment by investigating how cancer cells use 'hiding places' in the body to avoid chemotherapy drugs.

Scientists find genetic key to why some cancer patients don't respond to treatment

January 5, 2012
(Medical Xpress) -- Researchers from Newcastle University have identified a gene variation carried by 20% of the population which can significantly affect how patients with a rare type of blood cancer will respond to treatment.

DNA abnormalities may contribute to cancer risk in people with type 2 diabetes

July 14, 2013
A type of genetic abnormality linked to cancer is more common in people with type 2 diabetes than the rest of the population, a new study has found.

New markers could improve treatment and survival in acute lymphoblastic leukaemia

December 21, 2012
Acute lymphoblastic leukaemia, the most common paediatric cancer, has been the subject of study in the PhD thesis of ElixabetLópez.In the work entitled New genetic markers for treatment personalization in paediatric Acute ...

Cancer Research UK launches trial of new drug to treat acute childhood leukaemia

January 27, 2012
Cancer Research UK’s Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.